A novel biocontrol approach using bacterial volatile organic compounds (VOCs) produced by Chromobacterium spp. to inhibit fungal pathogens responsible for post-harvest rot in cranberries and other fruits and vegetables. Demonstrated broad-spectrum antifungal activity offers a potential alternative to synthetic fungicides.
This research program centers on the discovery and development of volatile organic compounds (VOCs) produced by Chromobacterium spp. as a natural biocontrol strategy for reducing post-harvest fungal losses in fruits and vegetables. The team has demonstrated that VOCs emitted by Chromobacterium vaccinii and related bacterial isolates from bog soils inhibit the growth of fungal pathogens responsible for cranberry post-harvest rot, including Phoma, Colletotrichum, and Coleophoma. Importantly, the same compounds show activity against a broad range of fungal targets, including human dermatophytes, Trichoderma, and Phytophthora cinnamomi, suggesting significant versatility across agricultural and clinical applications.
The value proposition for industry partners lies in the potential to develop a new class of biofungicides or post-harvest treatments derived from naturally produced volatiles. Such an approach could reduce dependence on synthetic chemical fungicides, address growing consumer and regulatory demand for sustainable crop protection, and provide a new tool for managing losses in the supply chain.
Key features and findings:
Planned validation work:
This technology is currently at an early-to-mid stage of development. The proof-of-concept has been established through published peer-reviewed research demonstrating fungistatic VOC activity from C. vaccinii against fungal pathogens. However, key gaps remain: individual active compounds have not yet been fully identified and assayed, and the technology has not yet been tested against post-harvest fungal complexes from fruits and vegetables beyond cranberry. Further validation, including compound identification, efficacy testing on additional crops, and plant safety assessment, is needed before commercial development can begin. The research team is actively seeking partnerships to advance this work toward practical application.
Midwestern University is a private, graduate-level health sciences institution with campuses in Downers Grove, Illinois, and Glendale, Arizona, known for interprofessional education and patient-centered training. Co-located clinics for human and animal care and advanced simulation centers let partners pilot technologies, generate evidence, and co-design solutions with practitioners. The university partners with regional hospital systems, community clinics, and veterinary networks across Chicago and Phoenix, providing access to diverse patient populations. Faculty engage in industry-sponsored studies and secure competitive federal support from NIH and HRSA; dedicated teams streamline IRB, contracting, and basic IP support.